NCT02833831View on ClinicalTrials.gov

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

June 2, 2016

Primary Completion Date

February 17, 2017

Study Completion Date

February 24, 2017

Conditions
Healthy
Interventions
DRUG

ALS-008176

Participants will receive a single dose of ALS-008176 orally.

DRUG

Placebo

Matching Placebo will be administered.

DRUG

Moxifloxacin

Participants will receive a single dose of moxifloxacin 400 mg.

Trial Locations (1)

Unknown

Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02833831 - Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants | Biotech Hunter | Biotech Hunter